Abstract
Radionuclide therapy is one of the pillars of Nuclear Medicine. The radionuclide therapy programme at the Institute of Nuclear Medicine started with the use of radioiodine (I-131) for treatment of the benign overactive thyroid syndromes (Grave’s disease, autonomy, etc) expressed by increased thyroid hormone output - thyrotoxicosis, followed by the use of I-131 to treat malignant thyroid cancer. The management and treatment of thyrotoxicosis and of thyroid cancer was jointly carried out with the departments of Endocrinology and Radiotherapy, respectively. The treatment of these two entities comprised the bulk of the work, and remain so to date. Treating benign thyroid disease did not require any major change in practice, as patients were treated in the department of Nuclear Medicine on an outpatient basis. However, for thyroid cancer patients, designated rooms had to be identified.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003 Jun; 15(4):193–8.
Solanki KK, Bomanji JB, Waddington WA, Ell PJ; Thyroid blocking policy-revisited. UK Administration of Radioactive Substances Advisory Committee. Nucl Med Commun. 2004 Nov; 25(11):1071–6. No abstract available.
Sawyer EJ, Cassoni AM, Waddington W, Bomanji JB, Briggs TW. Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma. Br J Radiol. 1999; 72(864):1225–9.
Syed R, Bomanji J, Nagabhushan N, Kayani I, Groves A, Waddington W, Cassoni A, Ell PJ. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma. J Nucl Med. 2006 Dec; 47(12):1927–35.
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, Aldridge M, Waddington W, Gaze MN. 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma. J Nucl Med. 2011 Jul; 52(7):1041–7. Epub 2011 Jun 16.
Author information
Consortia
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
University College NHS Foundation Trust and University College London. (2012). Treating Disease. In: FESTSCHRIFT The Institute of Nuclear Medicine 50 Years. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25123-8_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-25123-8_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-24714-9
Online ISBN: 978-3-642-25123-8
eBook Packages: MedicineMedicine (R0)